

## Control of breathing in obstructive sleep apnoea and in patients with the overlap syndrome

L. Radwan\*, Z. Maszczyk\*, A. Kozirowski\*, M. Koziej\*\*,  
J. Cieslicki\*\*, P. Sliwinski\*\*, J. Zielinski\*\*

*Control of breathing in obstructive sleep apnoea and in patients with the overlap syndrome. L. Radwan, Z. Maszczyk, A. Kozirowski, M. Koziej, J. Cieslicki, P. Sliwinski, J. Zielinski. ©ERS Journals Ltd 1995.*

**ABSTRACT:** In some patients obstructive sleep apnoea (OSA) may co-exist with chronic obstructive pulmonary disease (COPD) and respiratory failure; the so-called "overlap syndrome". Obstructive, hypercapnic patients have both blunted ventilatory and mouth occlusion pressure responses during CO<sub>2</sub> stimulation. The purpose of this study was to compare the pattern of breathing and CO<sub>2</sub> response between OSA patients and those with the overlap syndrome.

Twenty obese men with OSA and normal lung function (Group A), 11 obese men with overlap syndrome (Group B) and 13 healthy nonobese subjects (Group C) were examined. Lung function tests, breathing pattern, mouth occlusion pressure (P<sub>0.2</sub>) at rest, and respiratory responses during CO<sub>2</sub> rebreathing were investigated. Diagnosis of OSA was established by standard polysomnography.

There were no statistical differences between Groups A and B in apnoea-hypopnoea index (62 vs 54), mean arterial oxygen saturation (Sa<sub>o2</sub>) during sleep (85 vs 84%) and in body mass index (BMI) 34.3 vs 36.3 kg·m<sup>-2</sup>. Minute ventilation, mean inspiratory flow and P<sub>0.2</sub> at rest were increased in both groups of patients in comparison to controls. During CO<sub>2</sub> rebreathing, group A had normal ventilatory and P<sub>0.2</sub> responses, similar to controls, (2.7±1.1 vs 2.1±0.4 l·min<sup>-1</sup>·mmHg<sup>-1</sup> and 0.7±0.3 vs 0.71±0.25 cmH<sub>2</sub>O·mmHg<sup>-1</sup>, respectively). However, Group B had significantly decreased ventilatory and P<sub>0.2</sub> responses to CO<sub>2</sub> (0.71±0.23 l·min<sup>-1</sup>·mmHg<sup>-1</sup> and 0.34±0.17 cmH<sub>2</sub>O·mmHg<sup>-1</sup>, respectively).

This comparison showed that patients with OSA had normal CO<sub>2</sub> response when awake, whereas those with overlap syndrome had diminished CO<sub>2</sub> response when awake. It seems that co-existence of COPD with hypercapnic respiratory failure is the main cause of decreased CO<sub>2</sub> response in the overlap syndrome.

*Eur Respir J., 1995, 8, 542-545.*

Control of breathing in awake patients with obstructive sleep apnoea (OSA) has been evaluated by many authors with conflicting results. In some studies [1-4], sleep fragmentation due to apnoea was associated with blunted chemoreflexes; hypercapnic ventilatory and mouth occlusion pressure responses were decreased. Other studies [5-8] and our own [9], demonstrate normal respiratory responses during CO<sub>2</sub> stimulation in normocapnic OSA patients. However, some authors [6, 10], found that, ventilatory CO<sub>2</sub> response was depressed in OSA patients with chronic hypercapnia.

During recent years, we have studied patients with OSA and also a group of patients with OSA and co-existing chronic obstructive pulmonary disease (COPD) and respiratory failure, so-called "overlap syndrome", as proposed by FLENLEY [11, 12]. The purpose of this study was to compare the breathing pattern and CO<sub>2</sub> response in patients with OSA and normal lung function with that in patients with overlap syndrome and hypercapnic respiratory failure.

\*Lung Function Laboratory and \*\*Dept of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warszawa, Poland.

Correspondence: L. Radwan  
Lung Function Lab.  
Institute of Tuberculosis and Lung Diseases  
Plocka 26  
01-138 Warszawa  
Poland

Keywords: Breathing pattern  
CO<sub>2</sub> chemosensitivity  
hypercapnic respiratory failure  
obstructive sleep apnoea  
overlap syndrome

Received: April 22 1994  
Accepted after revision January 14 1995

### Material and methods

Two groups of patients and a control group were investigated. Group A consisted of 20 obese men with OSA, without respiratory symptoms and with almost normal lung function results. Their mean age was 45±6 yrs, and body mass index (BMI) 34.4±6.3 kg·m<sup>-2</sup>. Group B consisted of 11 obese men with OSA and hypercapnic respiratory failure due to COPD (overlap syndrome). Their mean age was 53±8 yrs, and BMI 36.3±5.8 kg·m<sup>-2</sup>.

Group C consisted of 13 healthy, nonobese subjects with no sleep complaints and no sleep symptoms typical of OSA. Their mean age was 34±7 yrs, and BMI was 22.3±3.0 kg·m<sup>-2</sup>.

In all Group A and B patients, lung function tests, including volumes, maximal expiratory flows and airway resistance were performed with the use of body plethysmograph (Masterlab, Jaeger). Predicted values were those of the European Coal and Steel Community (ECSC) [13]. Blood gases were measured in arterialized capillary blood using a Corning 168 analyser.

The pattern of breathing, minute ventilation ( $\dot{V}_E$ ) and mouth occlusion pressure (P0.2) were measured with the use of a pneumotachograph, electromanometer and occlusion pressure valve, with the subject in the sitting position, awake and at rest. Ventilatory and mouth occlusion pressure responses during CO<sub>2</sub> rebreathing test, according to Read, were measured with the same set of equipment. CO<sub>2</sub> concentration before and during rebreathing was measured with the use of a mass spectrometer (Centronix). Inspired volume, and end-tidal CO<sub>2</sub> were recorded continuously on a six-channel recorder (Watanabe). The respiratory response was evaluated from minute ventilation and mouth occlusion pressure slopes ( $\Delta\dot{V}_E/\Delta P_{CO_2}$ ) and  $\Delta P_{0.2}/\Delta P_{CO_2}$  and from absolute values of ventilation and P0.2 at an end-tidal carbon dioxide tension (P<sub>ET,CO<sub>2</sub></sub>) 60 mmHg. The strength of respiratory muscles, maximal inspiratory (MIP) and expiratory (MEP) pressures, were measured at the mouth with the use of a manometer.

The diagnosis of OSA was established by standard polysomnography, and was performed using a computerized system (Somnostar 4100; Sensormedics). Sleep staging was carried out according to standard criteria [14]. Sleep efficiency was defined as percentage ratio of total sleep time to sleep period. Breathing disorders were classified as obstructive, central or mixed. Apnoea was defined as cessation of nasal or oral airflow for at least 10 s [15]. Hypopnoea was defined as a 50% decrease of thoracic and abdominal respiratory signal for 10 s or more [16]. Significant desaturation was defined as a fall in SaO<sub>2</sub> of 4% or more from the preceding stable SaO<sub>2</sub> when asleep [17]. Sleep and respiration were scored visually on a high resolution screen. The apnoea+hypopnoea index (AHI) was calculated from hand-scoring of polygraphic data as a mean number of disordered breathing episodes for one hour of sleep. AHI was considered diagnostic for OSA when  $\geq 10$ .

Statistical significance of differences between data were tested with the unpaired t-test.

## Results

Polysomnography confirmed the diagnosis of OSA in both groups of patients. There were no statistical differences between Groups A and B in BMI, AHI and mean SaO<sub>2</sub> during sleep (table 1). Lung function values were within normal limits in Group A, with the exception of a decreased mean value of maximal expiratory flow at 25% forced vital capacity (MEF25). Mean arterial oxygen tension (PaO<sub>2</sub>) was 8.9 kPa (66.7 mmHg). All patients were normocapnic (table 2), with the exception of one having an arterial carbon dioxide tension (Paco<sub>2</sub>) 6.4 kPa (48 mmHg).

All patients in Group B had symptoms of bronchial obstruction, lung hyperinflation, moderate hypoxaemia, slight hypercapnia and increased serum bicarbonate concentration. They also had lower values of maximal inspiratory and expiratory pressures, probably due to lung hyperinflation (table 2).

In both groups, we found increased resting ventila-

Table 1. – Results of polysomnography in patients with OSA (Group A) and overlap syndrome (Group B)

	Group A (n=20)	Group B (n=11)	p-value
Age yrs	45±6	53±8	<0.01
BMI kg·m <sup>-2</sup>	34.3±6.3	36.3±5.8	NS
Sleep efficiency %	67±10	83±14	<0.01
AHI	62±19	54±22	NS
Mean SaO <sub>2</sub> during sleep %	85±5	84±3	NS

BMI: body mass index; AHI: apnoea/hypopnoea index; SaO<sub>2</sub>: arterial oxygen saturation; NS: nonsignificant; OSA: obstructive sleep apnoea.

Table 2. – Mean results of lung function tests in patients with OSA (Group A) and overlap syndrome (Group B)

	Group A (n=20)	Group B (n=11)	p-value
FVC % pred	107±16	64±19.1	<0.001
FEV <sub>1</sub> % pred	98±15	43±15	<0.001
FEV <sub>1</sub> /FVC %	76±5	53±11.8	<0.001
Raw kPa·l <sup>-1</sup> ·s	0.22±0.06	0.73±0.38	<0.001
TGV % pred	104±20	140±42	<0.01
TLC % pred	105±10	102±16	NS
PaO <sub>2</sub> kPa	8.9±0.8	6.8±0.6	<0.001
mmHg	66.7±6.1	50.8±4.7	
Paco <sub>2</sub> kPa	5.3±0.5	6.8±1.0	<0.001
mmHg	40.0±3.6	50.7±7.7	
HCO <sub>3</sub> mmol·l <sup>-1</sup>	23.3±3.6	29.7±6.2	<0.001
MIP cmH <sub>2</sub> O	120±37	77±33	<0.05
MEP cmH <sub>2</sub> O	198±47	131±32	<0.001

Data are presented as mean±SD. FVC: forced vital capacity; % pred: percentage of predicted value; FEV<sub>1</sub>: forced expiratory volume in one second; Raw: airways resistance; TGV: thoracic gas volume; TLC: total lung capacity; PaO<sub>2</sub>: arterial oxygen tension; Paco<sub>2</sub>: arterial carbon dioxide tension; MIP: maximal inspiratory pressure; MEP: maximal expiratory pressure; OSA: obstructive sleep apnoea; NS: nonsignificant.

tion. In Group A it was due mainly to increased tidal volume (V<sub>T</sub>), and in Group B it was predominantly due to higher frequency of breathing. Patients in Group B had lower V<sub>T</sub>, higher frequency of breathing and higher mouth occlusion pressure compared with Group A. Mean inspiratory flow (V<sub>T</sub>/T<sub>I</sub>) and mouth occlusion pressure (P0.2) were increased in both groups in comparison to controls (table 3).

During CO<sub>2</sub> rebreathing, Group A patients had ventilatory and P0.2 responses similar to those of the control group. However, Group B patients had significantly decreased ventilatory and P0.2 responses during rebreathing (table 4) in comparison to controls. Also, absolute values of ventilation and P0.2 at P<sub>ET,CO<sub>2</sub></sub> of 60 mmHg were decreased in Group B patients. The differences in respiratory response between Group A and B patients were also statistically significant (p<0.001).

## Discussion

The pattern of breathing was abnormal in both groups of patients with OSA in comparison to control, nonobese

Table 3. – Pattern of breathing during resting ventilation in patients with OSA (Group A), overlap syndrome (Group B) and in control subjects (Group C)

	Group A (n=20)	Group B (n=11)	Group C (n=13)
$\dot{V}_E$ $l \cdot \text{min}^{-1}$	15.3±3.1***	12.8±3.5**	9.2±2.5
$V_T$ $l$	0.95±0.19***	0.59±0.17	0.62±0.18
$T_i$ $s$	1.6±0.5	1.07±0.21	1.8±0.82
$T_{\text{tot}}$ $s$	3.8±0.55	2.78±0.55**	4.3±1.5
$V_T/T_i$ $l \cdot s^{-1}$	0.62±0.13***	0.56±0.14***	0.37±0.10
$P_{0.2}$ $\text{cmH}_2\text{O}$	3.6±1.6**	6.4±3.6***	2.2±0.4

$\dot{V}_E$ : minute ventilation;  $V_T$ : tidal volume;  $T_i$ : inspiratory time;  $T_{\text{tot}}$ : total breath duration;  $V_T/T_i$ : mean inspiratory flow;  $P_{0.2}$ : mouth occlusion pressure; OSA: obstructive sleep apnoea. In statistical analysis, Group A and B were compared with Group C. \*\*\*:  $p < 0.001$ ; \*\*:  $p < 0.01$ .

Table 4. – Ventilatory and mouth occlusion pressure responses during  $\text{CO}_2$  rebreathing test in patients with OSA (Group A), overlap syndrome (Group B) and in control subjects (Group C)

	Group A (n=20)	Group B (n=11)	Group C (n=13)
$\Delta \dot{V}_E / \Delta P_{\text{CO}_2}$ $l \cdot \text{min}^{-1} \cdot \text{mmHg}^{-1}$	2.7±1.1	0.71±0.23***	2.1±0.4
$\Delta P_{0.2} / \Delta P_{\text{CO}_2}$ $\text{cmH}_2\text{O} \cdot \text{mmHg}^{-1}$	0.7±0.3	0.34±0.17***	0.71±0.25
$\dot{V}_E$ at $P_{\text{ET},\text{CO}_2}$ 60 $\text{mmHg}$ $l \cdot \text{min}^{-1}$	66.7±21.4	26.7±10.9***	58.8±15.7
$P_{0.2}$ at $P_{\text{ET},\text{CO}_2}$ 60 $\text{mmHg}$ $\text{cmH}_2\text{O}$	15.1±5.9	8.8±4.7***	18.9±8.0

$\dot{V}_E$ : minute ventilation;  $P_{\text{CO}_2}$ : carbon dioxide tension;  $P_{0.2}$ : mouth occlusion pressure;  $P_{\text{ET},\text{CO}_2}$ : end-tidal carbon dioxide tension; OSA: obstructive sleep apnoea. In statistical analysis, Group A and B were compared with Group C. \*\*\*:  $p < 0.001$ ; \*\*:  $p < 0.01$ .

subjects. Patients with the overlap syndrome had a higher frequency of breathing and lower tidal volume than patients with OSA. Mean inspiratory flow and mouth occlusion pressure were increased in both groups, indicating higher neuromuscular output.

The mechanism of increased neuromuscular output in OSA patients is not yet established, but obesity and changed thoracic mechanics may play a role. It is documented that chest wall compliance is reduced in obese patients, due to deposition of adipose tissue [18, 19]. This change in thoracic elasticity may enhance so-called "load compensation reflex" similar to healthy subjects with an added elastic [20] or mass load [21].

Another factor causing higher neuromuscular output in awake OSA patients might be increased hypoxic drive due to slight hypoxaemia. In patients with overlap syndrome, the change in breathing pattern was additionally affected by disturbed mechanics of breathing and gas exchange.

In our study,  $\text{CO}_2$  sensitivity in awake OSA patients was in the normal range, similar to the values of the control group. This is in accordance with our earlier data [9], and that of others [5–7]. However, in patients with the overlap syndrome and hypercapnia, ventilatory and mouth occlusion pressure responses were decreased.

There are few studies of  $\text{CO}_2$  sensitivity in patients with OSA and co-existing hypercapnia. GARAY *et al.* [6] demonstrated an inverse relationship between waking  $P_{\text{CO}_2}$  and hypercapnic ventilatory response. BERTHON-JONES and SULLIVAN [22] and, more recently, VERBRAECKEN *et al.* [10] also found decreased ventilatory response in OSA patients with hypercapnia. In addition, hypercapnic patients with COPD and without sleep disorders had decreased  $\text{CO}_2$  sensitivity [23–25].

In obstructive patients with the overlap syndrome, a low ventilatory response to  $\text{CO}_2$  is caused mainly by disturbed lung mechanics and gas exchange. Mouth occlusion pressure response to  $\text{CO}_2$  in patients with the overlap syndrome may have been affected in several ways. In these patients with chronic hypercapnia, we found increased blood bicarbonate concentration. This factor inhibits  $\text{CO}_2$  sensitivity and decreases mouth occlusion pressure response [23–25]. Some authors [26] have postulated that hyperinflation of the lung may also decrease mouth occlusion pressure response. As hyperinflation was also found in patients with overlap syndrome, this factor has to be taken into account. In addition, lower respiratory muscle strength and constitutional or genetic factors may be responsible for lowered ventilatory and mouth occlusion pressure responses in patients with overlap syndrome (Group B), as has been suggested in hypercapnic COPD patients [27].

Comparison of the two groups of patients showed that those with OSA had normal  $\text{CO}_2$  response, whereas those with the overlap syndrome had diminished  $\text{CO}_2$  response like hypercapnic patients with COPD alone. It seems that co-existence of COPD with hypercapnic respiratory failure is the main cause of decreased  $\text{CO}_2$  response in overlap syndrome. However, breathing pattern was abnormal in both groups of patients with OSA, probably as a consequence of obesity and changed thoracic mechanics.

## References

1. Gold AR, Schwartz AR, Wise RA, Smith PL. Pulmonary function and respiratory chemosensitivity in moderately obese patients with sleep apnea. *Chest* 1993; 103: 1325–1329.
2. Lopata M, Onal E. Mass loading, sleep apnea and the pathogenesis of obesity hypoventilation. *Am Rev Respir Dis* 1982; 126: 640–645.
3. Perez T, Didier A, Doyon B, *et al.* Improvement in daytime ventilatory responses to  $\text{CO}_2$  with or without inspiratory load after CPAP therapy for obstructive sleep apnoea syndrome. *Eur Respir J* 1991; 4 (Suppl. 14): 585s.
4. Sforza E, Krieger J, Weitzenblum E, Apprill M, Lampert E, Ratamaharo J. Long-term effects of treatment with nasal continuous positive airway pressure on daytime lung function and pulmonary hemodynamics in patients with obstructive sleep apnea. *Am Rev Respir Dis* 1990; 141: 866–870.
5. Breska B, Andreas S, Kreuzer H. Ventilatory response to  $\text{CO}_2$  in eucapnic patients with obstructive sleep apnea. *J Sleep Res* 1992; 1 (Suppl. 1): 247.
6. Garay SM, Rapoport D, Sorkin B, Epstein H, Feinberg

- I, Goldring RM. Regulation of ventilation in the obstructive sleep apnea syndrome. *Am Rev Respir Dis* 1981; 124: 451–457.
7. Rajagopal KR, Abbrecht PH, Tellis CJ. Control of breathing in obstructive sleep apnea. *Chest* 1984; 85: 174–180.
  8. Verbraecken J, Willemen M, Wittesaele W, De Cock W, Van De Heyning P, De Backer W. CO<sub>2</sub> drive in patients with obstructive sleep apnoea: acute and chronic effects of CPAP. *Eur Respir J* 1993; 6 (Suppl. 17): 399s.
  9. Radwan L, Maszczyk Z, Cieslicki J, Sliwinski P, Koziorowski A. Control of breathing in patients with obstructive sleep apnea syndrome. *Eur Respir J* 1992; 5 (Suppl. 15): 161s.
  10. Verbraecken J, Willemen M, Wittesaele W, DeCook W, Van De Heyning P, De Backer W. Chronic CO<sub>2</sub> drive in patients with obstructive sleep apnea, heavy snoring and health controls. *Chest* 1993; 103 (Suppl.): 321s.
  11. Flenley DC. Chronic obstructive lung disease. In: Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep medicine. Philadelphia, Saunders, 1989: pp. 601–610.
  12. Douglas NJ, Flenley DC. Breathing during sleep in patients with obstructive lung disease. *Am Rev Respir Dis* 1990; 141: 1055–1070.
  13. Quanjer PhH. Standardized lung function testing. *Bull Eur Physiopathol Respir* 1983; 19 (Suppl. 5): 7–10.
  14. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subject. Los Angeles, Brain Research Institute, 1968.
  15. Guilleminault C, van den Hoed J, Miller M. Clinical overview of the sleep apnea syndromes. In: Guilleminault C, Dement W. eds. Sleep Apnea Syndromes. New York, Alan R. Liss, 1978; pp. 1–12.
  16. Gould GA, Whyte KF, Rhind GB, *et al.* The sleep hypopnea syndrome. *Am Rev Respir Dis* 1988; 137: 895–898.
  17. Block AJ, Boysen PG, Wynne JW, Hunt LA. Sleep apnea, hypopnoea and oxygen desaturation in normal subjects: strong male predominance. *N Engl J Med* 1979; 300: 513–517.
  18. Rochester DF, Enson Y. Current concepts in the pathogenesis of the obesity-hypoventilation syndrome. *Am J Med* 1974; 57: 402–420.
  19. Luce JM. Respiratory complications of obesity. *Chest* 1980; 78: 626–631.
  20. Shekleton M, Lopata M, Evenich MJ, Lourenco RV. Effect of elastic loading on mouth occlusion pressure during CO<sub>2</sub> rebreathing in man. *Am Rev Respir Dis* 1976; 114: 341–346.
  21. Sharp JT, Henry JP, Sweany SK, Meadows WR, Pietras RJ. Effects of mass loading the respiratory system in man. *J Appl Physiol* 1964; 19: 959–966.
  22. Berthon-Jones M, Sullivan CE. Time course of change in ventilatory response to CO<sub>2</sub> with long-term CPAP therapy for obstructive sleep apnea. *Am Rev Respir Dis* 1987; 135: 144–147.
  23. Dempsey JA, Forster HV. Mediation of ventilatory adaptations. *Physiol Rev* 1982; 62: 262–346.
  24. Park SS. Respiratory control in chronic obstructive pulmonary diseases. *Clin Chest Med* 1980; 1: 73–80.
  25. Radwan L, Maszczyk Z, Chodosowska E, Koziorowski A. Control of breathing in patients with chronic airflow limitation and hypercapnic respiratory failure. *Eur Respir J* 1993; 6 (Suppl. 17): 399s.
  26. Erbland ML, Ebert RV, Snow SL. Interaction of hypoxia and hypercapnia on respiratory drive in patients with COPD. *Chest* 1990; 97: 1289–1294.
  27. Mountain R, Zwillich C, Weil J. Hypoventilation in obstructive lung disease: the role of familial factors. *N Engl J Med* 1978; 298: 521–525.